Big pharmas face short-term disruption from Japan, but Leerink Swann believes it should be...


Big pharmas face short-term disruption from Japan, but Leerink Swann believes it should be "muted relative to other industries.” Of the biggest pharma names, Bristol Myers Squibb (BMY) is the least exposed, while Novartis (NVS) has the most exposure, with 8% of total revenue from Japan. GlaxoSmithKline (GSK) has the most bottom-line exposure.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs